[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.130.145. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correction
February 9, 2009

Error in Financial Disclosure in: Half- vs Full-Dose Trivalent Inactivated Influenza Vaccine (2004-2005): Age, Dose, and Sex Effects on Immune Responses

Arch Intern Med. 2009;169(3):304. doi:10.1001/archinternmed.2008.614

Error in Financial Disclosure. In the Original Investigation by Engler et al titled “Half- vs Full-Dose Trivalent Inactivated Influenza Vaccine (2004-2005): Age, Dose, and Sex Effects on Immune Responses” published in the December 8/22, 2008 issue of the Archives (2008;168(22):2405-2414), an error occurred in the Financial Disclosure on page 2413. The Financial Disclosure should have read as follows:

Financial Disclosure: Dr Keitel has received research support from Protein Sciences Inc and Novartis Vaccines. Dr Nichol has served as a consultant for the influenza vaccine manufacturers sanofi pasteur, GlaxoSmithKline Biologicals, CSL Biotherapies, Novartis, and MedImmune and has received research funding from sanofi pasteur and GlaxoSmithKline Biologicals. Dr Treanor has received research support from Protein Sciences, Merck, Wyeth, GlaxoSmithKline, Antigen Express, Mercia Pharma, VaxInnate, Ligocyte, Sanofi, and CSL Biotherapies; has served as a consultant/scientific advisory board member for AlphaVax, Epimmune, Dynavax, Immune Targeting Systems, Pulmatrix, Powdermed, PaxVax, and Toyama; and has served as a Data Safety Monitoring Board member for Medimmune and Novavax.”

First Page Preview View Large
First page PDF preview
First page PDF preview
×